^
    Back
    Association details:
    Biomarker:ST6GAL1 elevation
    Cancer:Hepatocellular Cancer
    Drug:Lenvima (lenvatinib) (c-KIT inhibitor, FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PDGFR α antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    AACR 2021
    Title:

    351 - Serum ST6GAL1 is a novel biomarker for predicting efficacy of tyrosine kinase inhibitors in hepatocellular carcinoma by detecting FGF19 expressing tumor

    Published date:
    03/10/2021
    Excerpt:
    ...lenvatinib (LEN), or sorafenib (SOR)...In TKI-treated HCC patients with high baseline serum ST6GAL1 levels, LEN therapy showed significantly longer survival than SOR.
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    ST6GAL1 is a novel serum biomarker for lenvatinib-susceptible FGF19-driven hepatocellular carcinoma

    Published date:
    12/07/2020
    Excerpt:
    Among serum ST6GAL1-high HCC patients who underwent TKI therapy, lenvatinib therapy showed significantly better survival than sorafenib….serum ST6GAL may be a novel biomarker that identifies lenvatinib-susceptible FGF19-driven HCC.
    DOI:
    10.1158/1078-0432.CCR-20-3382